-
JACEP Oct 1979
Review
Topics: Acute Kidney Injury; Adolescent; Aged; Aminopyridines; Anemia, Hemolytic; Animals; Chemical and Drug Induced Liver Injury; Child, Preschool; Dogs; Female; Humans; Infant, Newborn; Lacrimal Apparatus Diseases; Male; Methemoglobinemia; Middle Aged; Phenazopyridine; Urinary Tract Infections
PubMed: 385954
DOI: 10.1016/s0361-1124(79)80409-8 -
International Urogynecology Journal Mar 2022Previous studies have found that administration of phenazopyridine decreased short-term urinary retention following surgery but other more recent trials have shown mixed...
INTRODUCTION AND HYPOTHESIS
Previous studies have found that administration of phenazopyridine decreased short-term urinary retention following surgery but other more recent trials have shown mixed results. This study sought to investigate the potential benefit of preoperative administration of oral phenazopyridine in relation to the prevention of short-term urinary retention following urogynecologic surgery.
METHODS
This is a retrospective cohort study of a convenience sample of women undergoing urogynecologic surgery from June 2016 to March 2019. Following surgery, subjects underwent a standardized retrograde voiding trial. The data had previously been gathered from a prior prospective trial at our institution (Kesty et al. Int Urogynecol J 31(9):1899-1905, 11). Chart review was performed to determine whether patients that received 200 mg of preoperative oral phenazopyridine to better visualize ureteral efflux during cystourethroscopy were more or less likely to pass their postoperative voiding trial. Bivariate statistical analysis was performed as well as a multivariate logistic regression model.
RESULTS
A total of 165 subjects were included in the final analysis; 100 who did not receive preoperative phenazopyridine and 65 who did receive phenazopyridine. There was no statistical difference between voiding trial pass rates following urogynecologic surgery between those who did not receive preoperative phenazopyridine compared to those who did [77% (77/100) and 82% (53/65), respectively, p = 0.37)]. The multivariate logistic regression model demonstrated no difference in postoperative voiding trial pass rates among those who received preoperative phenazopyridine compared to those who did not (OR 1.7, 95% CI: 0.53, 5.8).
CONCLUSIONS
Preoperative administration of oral phenazopyridine does not decrease short-term urinary retention following urogynecologic surgery.
Topics: Clinical Trials as Topic; Cystoscopy; Female; Humans; Phenazopyridine; Postoperative Complications; Prospective Studies; Retrospective Studies; Urinary Retention
PubMed: 33580812
DOI: 10.1007/s00192-021-04699-w -
Journal of Oncology Pharmacy Practice :... Mar 2020Phenazopyridine is a urinary tract analgesic indicated for short-term treatment of irritation in the lower urinary tract. Despite the lack of evidence for extended use,...
BACKGROUND
Phenazopyridine is a urinary tract analgesic indicated for short-term treatment of irritation in the lower urinary tract. Despite the lack of evidence for extended use, it is often used in varying durations for supportive care for cancer patients with radiation-induced cystitis. The objective of this study was to compare the incidence of adverse drug reactions in patients with radiation cystitis receiving long-term phenazopyridine (>14-day supply) compared to a matched comparator group.
METHODS
This retrospective cohort study compared adverse events among cancer patients with and without phenazopyridine exposure. Included patients received radiation and at least one chronic medication between 1 July 2008 and 30 June 2017. The phenazopyridine group also received >14-day supply of phenazopyridine during the study period. Patients were matched based on gender, age (±5 years), cancer diagnosis, and palliative or curative treatment intent. Data collection occurred at baseline, during the time of presumed exposure, and through the end of the study period for surveillance purposes.
RESULTS
A total of 272 patients received phenazopyridine for >14-day supply during the study period. Of these, 90 patients were included and matched to an equal number of patients in the comparator group. The included patients were similar between groups and were largely male with a diagnosis of prostate cancer. Most patients received between a 30- and 60-day supply of phenazopyridine. There were a total of 13 adverse drug reactions in the phenazopyridine group and 18 in the comparator group ( = 0.32). No differences were identified between the phenazopyridine and comparator groups for the incidence of individual adverse drug reactions, emergency department visits, hospitalizations, or new diagnoses of hepatocellular or colorectal cancer.
CONCLUSION
There was no difference in adverse drug reactions among patients receiving phenazopyridine for >14 days compared to a matched comparator group. The overall incidence of adverse events in both groups was low.
Topics: Aged; Cohort Studies; Cystitis; Drug Administration Schedule; Humans; Male; Middle Aged; Phenazopyridine; Radiation Injuries; Retrospective Studies
PubMed: 31006341
DOI: 10.1177/1078155219842646 -
The Annals of Pharmacotherapy Jun 2005To report a case of sulfhemoglobinemia in a patient receiving phenazopyridine for a urinary tract infection.
OBJECTIVE
To report a case of sulfhemoglobinemia in a patient receiving phenazopyridine for a urinary tract infection.
CASE SUMMARY
A 63-year-old white woman presented to the emergency department with complaints of fatigue and bluish discoloration of her body that had gradually progressed over the previous 6-8 weeks. About 4 months prior to presenting to the emergency department, she had started taking phenazopyridine, an over-the-counter medication for symptoms of dysuria. Because the cyanosis did not improve after the patient received oxygen and methylene blue, sulfhemoglobinemia was suspected and confirmed by spectrophotometer analysis.
DISCUSSION
Sulfhemoglobin is a green-pigmented molecule containing a sulfur atom in one or more of the porphyrin rings. It is a rare cause of cyanosis, which is usually drug induced. Sulfhemoglobinemia is suspected when a cyanotic patient has normal to near-normal oxygen tension, laboratory reports of elevated methemoglobin, and does not respond to methylene blue therapy. Sulfhemoglobinemia is relatively rare, despite the widespread use of drugs that have been reported to cause it. Predisposing factors, such as chronic constipation, present in our patient, have been suggested as a source of hydrogen sulfide.
CONCLUSIONS
This case of sulfhemoglobinemia, which occurred after the patient took phenazopyridine, is considered a probable adverse event according to the Naranjo probability scale.
Topics: Administration, Oral; Female; Humans; Middle Aged; Phenazopyridine; Sulfhemoglobinemia; Urinary Tract Infections
PubMed: 15886294
DOI: 10.1345/aph.1E557 -
Urologic Nursing Dec 1996
Review
Topics: Anesthetics, Local; Humans; Patient Education as Topic; Phenazopyridine
PubMed: 9258059
DOI: No ID Found -
Female Pelvic Medicine & Reconstructive... 2019The aims of this study were to determine the efficacy of phenazopyridine when used intraoperatively to assess ureteral patency and to investigate factors that may...
OBJECTIVES
The aims of this study were to determine the efficacy of phenazopyridine when used intraoperatively to assess ureteral patency and to investigate factors that may influence its efficacy.
METHODS
This is a retrospective chart review performed at the Olive View-UCLA Medical Center, a Los Angeles County teaching hospital, from January 2014 through July 2016. Patients undergoing cystoscopy at the time of gynecologic surgery were identified via department case logs. All women receiving preoperative oral phenazopyridine were included. If ureteral flow was unable to be visualized with phenazopyridine alone, the medication was deemed ineffective, and sodium fluorescein was given intraoperatively. Patients were divided into a phenazopyridine effective or phenazopyridine ineffective group. Patient demographics, renal function, intraoperative fluids and urine output, estimated blood loss, timing and dose of medication administration, and complications were gathered from the chart and compared between groups using Fisher exact test, 2-sample t test, Wilcoxon test, and logistic regression for multivariable analysis. P < 0.05 was determined to be significant.
RESULTS
Preoperative phenazopyridine was effective in 190 (91.8%) of 207 patients. It was ineffective in 17 patients who then required intraoperative sodium fluorescein. The group in which phenazopyridine was effective was more likely to have been given a 200-mg (vs 100-mg) dose (P = 0.02) and had lower intraoperative urine output (median, 450 vs 800 mL; P = 0.002).
CONCLUSIONS
Preoperative oral phenazopyridine is effective in more than 90% of cases to detect during gynecologic surgery. A higher phenazopyridine dose and lower intraoperative urine output were associated with increased efficacy.
Topics: Administration, Oral; Adult; Aged; Coloring Agents; Cystoscopy; Female; Fluorescein; Gynecologic Surgical Procedures; Humans; Intraoperative Complications; Intraoperative Period; Middle Aged; Phenazopyridine; Preoperative Period; Retrospective Studies; Surgical Wound; Ureter; Urine
PubMed: 29300258
DOI: 10.1097/SPV.0000000000000540 -
Irish Journal of Medical Science Nov 1985
Topics: Adult; Aminopyridines; Female; Humans; Methemoglobinemia; Oxygen; Phenazopyridine
PubMed: 4093270
DOI: 10.1007/BF02937219 -
British Medical Journal Oct 1976
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Humans; Phenazopyridine; Pyridines; Urinary Tract Infections
PubMed: 990717
DOI: 10.1136/bmj.2.6040.850 -
Lancet (London, England) Jan 1969
Topics: Aged; Anemia, Hemolytic; Anti-Infective Agents, Urinary; Female; Humans; Phenazopyridine
PubMed: 4178260
DOI: 10.1016/s0140-6736(69)91157-x